Skip to content
Review Open access

The gut microbiome-immune-antioxidant axis: Redox-driven host-microbial crosstalk as a determinant of cancer immunotherapy response

Sep 2026 · Eurasian Journal of Medicine and Oncology · 0 citations

TL;DR

The gut microbiome, immune, and antioxidant (GIA) axis is introduced as a unifying, systems-level conceptual framework to explain treatment heterogeneity and optimize cancer immunotherapy outcomes to overcome therapeutic resistance and transition host-microbiome-immune integration from conceptual promise to clinical reality.

Abstract

Introduction: The gut microbiome, host redox homeostasis, and immune regulation are mechanistically interdependent. However, their integrated role in driving resistance to immune checkpoint inhibitors remains incompletely defined.Objective: This review introduces the gut microbiome, immune, and antioxidant (GIA) axis as a unifying, systems-level conceptual framework to explain treatment heterogeneity and optimize cancer immunotherapy outcomes.Scope: We synthesize current mechanistic and translational evidence linking microbiota-derived metabolites, including short-chain fatty acids, bile acids, and tryptophan derivatives, to oxidative stress responses, mitochondrial fitness, and anti-tumor immune competence across colorectal, hepatobiliary, and neuro-oncologic malignancies.Key findings: Disruption of the GIA network promotes immunotherapy resistance through excessive oxidative burden, pathological Nrf2 signaling, and the expansion of immunosuppressive myeloid populations. Conversely, targeted microbiome interventions, including probiotics, postbiotics, and fecal microbiota transplantation, can successfully restore redox-immune equilibrium, remodel the tumor microenvironment, and enhance the efficacy of checkpoint blockade.Conclusion: We propose a precision immuno-oncology framework utilizing composite GIA-axis biomarker profiling for patient stratification. Integrating these multidisciplinary insights identifies actionable translational opportunities to overcome therapeutic resistance and transition host-microbiome-immune integration from conceptual promise to clinical reality.

Read PDF

Similar papers

Review Open access Oct 2026

Gut Microbiota–Host Redox Crosstalk: Molecular Mechanisms, Disease Pathogenesis, and Therapeutic Interventions

The crosstalk between the gut microbiota and the host redox system is essential for maintaining intestinal homeostasis and systemic health. Disruption of this bidirectional interaction impairs redox balance, promotes oxidative stress, and contributes to the initiation and progression of a wide range of diseases, includ...

Shuai-Hu Chen, Yu-Long Yin, Jie Yin et al. · 0 citations
Review Open access Aug 2026

The gut microbiota-tryptophan metabolism-immune axis in inflammatory bowel disease: Mechanisms and therapeutic prospects

ABSTRACT The gut microbiota–tryptophan (TRP) metabolism–immune axis is one of the core pathogenic mechanisms in inflammatory bowel disease (IBD). Physiologically, gut microbes convert dietary TRP into bioactive metabolites that regulate intestinal immune balance and barrier function via AHR. In IBD, this axis enters a...

Teng-Fei Wang, Xiao-Gan Wang, Wei-Chen Yuan · 0 citations
Review Open access Aug 2026

Gut-microbiota-mediated host immune modulation: mechanisms, pathological dysbiosis, and therapeutic frontiers

The mammalian immune system has evolved in constant dialogue with its diverse microbiota, forming an ecological and molecular partnership that is fundamental to health. This review examines how microbial communities shape immunity across developmental and functional axes, the immunological consequences of dysbiosis dur...

P. Babu, V. Prakash, Suja Subhash et al. · 0 citations
Review Open access Sep 2026

Gut microbiome-mediated primary and acquired resistance to immune checkpoint inhibitors in MSI-H/dMMR colorectal cancer: mechanisms, biomarkers, and therapeutic implications-a narrative review

Introduction Immune checkpoint inhibitors (ICIs) have transformed the management of microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) colorectal cancer (CRC). However, a substantial proportion of patients exhibit primary resistance or eventually develop acquired resistance, highlighting the need fo...

Marko Marjanovic, Nemanja Maletin, B. Kukic et al. · 0 citations
Review Open access Sep 2026

Gut microbiota–cancer crosstalk: emerging molecular targets for personalized cancer treatment- a comprehensive review

Cancer remains a major global health challenge, and growing evidence indicates that the gut microbiota plays an important role in cancer initiation, progression, metastasis, and response to treatment through complex interactions with host signaling, metabolism, and immunity. This comprehensive narrative review discusse...

P. Negi, Arpita Upreti, Preeti Budhlakoti et al. · 0 citations
Open access Sep 2026

Gut Microbiome Control of Tumor Immune Checkpoint Inhibitor Response: Mechanistic Insights and Clinical Translation

Here, we summarize available data on mechanisms by which the gut microbiota may affect immune checkpoint inhibitors (ICIs) and discuss potential therapeutic approaches targeting the microbiota. Gut microbiota could affect both antitumor immunity and immune-related toxicities through orchestration of the mucosal and sys...

Yusa Xie · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.